6/30/2015 - 9:46 AM EST - Telesta Therapeutics Inc. : announced today that it has submitted electronically, through its U.S. agent, a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for MCNA. MCNA is Telesta's novel biologic immunotherapeutic for the treatment of high-risk non-muscle invasive bladder cancer patients who have failed first-line BCG therapy. Telesta Therapeutics Inc.
shares T.TST are trading up $0.045 at $0.36.
